Cargando…

Role of (13)C methacetin breath test for non invasive staging of liver fibrosis in patients with chronic hepatitis C

BACKGROUND & OBJECTIVES: The development and evaluation of non invasive tests to assess liver fibrosis have been an active field of research. The present study was carried out to evaluate the role of (13)C-methacetin breath test (13)C- MBT) as a non invasive tool for liver fibrosis staging in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Fierbinteanu-Braticevici, Carmen, Papacocea, Raluca, Tribus, Laura, Cristian, Baicus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181145/
https://www.ncbi.nlm.nih.gov/pubmed/25222787
_version_ 1782337327822012416
author Fierbinteanu-Braticevici, Carmen
Papacocea, Raluca
Tribus, Laura
Cristian, Baicus
author_facet Fierbinteanu-Braticevici, Carmen
Papacocea, Raluca
Tribus, Laura
Cristian, Baicus
author_sort Fierbinteanu-Braticevici, Carmen
collection PubMed
description BACKGROUND & OBJECTIVES: The development and evaluation of non invasive tests to assess liver fibrosis have been an active field of research. The present study was carried out to evaluate the role of (13)C-methacetin breath test (13)C- MBT) as a non invasive tool for liver fibrosis staging in patients with chronic hepatitis C (CHC). METHODS: (13)C-Methacetin breath test was performed in 115 patients with CHC histologically proven and in 55 healthy controls. All patients and controls underwent routine liver function tests. The CHC patients underwent histological assesment of liver by percutaneous liver biopsy. The correlation between the (13)C-methacetin breath test and liver biopsy was tested using Kendall's rank correlation coefficients. The overall validity was expressed as area under receiver operating characteristic curve (AUROC) with 95%CI. RESULTS: Delta over baseline values (DOB) of CHC patients at 20 min were significantly reduced compared with control (16. 2 vs. 21. 06%, P<0.001). There were also significant differences between CHC patients and controls as regard the metabolization speed (dose /h at 20 min (17.80 vs 28.6, P<0.001) and metabolization capacity (cumulative recovery after 60 min (13.8 vs 20.4 P<0.001). The best (13)C-MBT parameter correlated with fibrosis was DOB at 20 min (r= - 0.596). The optimal cut-off for the diagnosis of advanced fibrosis (F≥3) was 15.2 per cent, with AUROC= 0.902, 95%CI: (0.851-0.938), a sensitivity of 82 per cent and a specificity of 80 per cent. DOB at 20 min predicted even better cirrhosis: AUROC = 0.932 95 per cent CI = 0.901-0.953, a sensitivity of 96 per cent and a specificity of 92 per cent. INTERPRETATION & CONCLUSIONS: Based on our findings the (13)C – methacetin breath test appears to be a promising tool to identify CHC patients with advanced fibrosis and to replace liver biopsy. Further studies need to be done to assess its potential to be used in regular clinical practice.
format Online
Article
Text
id pubmed-4181145
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-41811452014-10-14 Role of (13)C methacetin breath test for non invasive staging of liver fibrosis in patients with chronic hepatitis C Fierbinteanu-Braticevici, Carmen Papacocea, Raluca Tribus, Laura Cristian, Baicus Indian J Med Res Original Article BACKGROUND & OBJECTIVES: The development and evaluation of non invasive tests to assess liver fibrosis have been an active field of research. The present study was carried out to evaluate the role of (13)C-methacetin breath test (13)C- MBT) as a non invasive tool for liver fibrosis staging in patients with chronic hepatitis C (CHC). METHODS: (13)C-Methacetin breath test was performed in 115 patients with CHC histologically proven and in 55 healthy controls. All patients and controls underwent routine liver function tests. The CHC patients underwent histological assesment of liver by percutaneous liver biopsy. The correlation between the (13)C-methacetin breath test and liver biopsy was tested using Kendall's rank correlation coefficients. The overall validity was expressed as area under receiver operating characteristic curve (AUROC) with 95%CI. RESULTS: Delta over baseline values (DOB) of CHC patients at 20 min were significantly reduced compared with control (16. 2 vs. 21. 06%, P<0.001). There were also significant differences between CHC patients and controls as regard the metabolization speed (dose /h at 20 min (17.80 vs 28.6, P<0.001) and metabolization capacity (cumulative recovery after 60 min (13.8 vs 20.4 P<0.001). The best (13)C-MBT parameter correlated with fibrosis was DOB at 20 min (r= - 0.596). The optimal cut-off for the diagnosis of advanced fibrosis (F≥3) was 15.2 per cent, with AUROC= 0.902, 95%CI: (0.851-0.938), a sensitivity of 82 per cent and a specificity of 80 per cent. DOB at 20 min predicted even better cirrhosis: AUROC = 0.932 95 per cent CI = 0.901-0.953, a sensitivity of 96 per cent and a specificity of 92 per cent. INTERPRETATION & CONCLUSIONS: Based on our findings the (13)C – methacetin breath test appears to be a promising tool to identify CHC patients with advanced fibrosis and to replace liver biopsy. Further studies need to be done to assess its potential to be used in regular clinical practice. Medknow Publications & Media Pvt Ltd 2014-07 /pmc/articles/PMC4181145/ /pubmed/25222787 Text en Copyright: © Indian Journal of Medical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Fierbinteanu-Braticevici, Carmen
Papacocea, Raluca
Tribus, Laura
Cristian, Baicus
Role of (13)C methacetin breath test for non invasive staging of liver fibrosis in patients with chronic hepatitis C
title Role of (13)C methacetin breath test for non invasive staging of liver fibrosis in patients with chronic hepatitis C
title_full Role of (13)C methacetin breath test for non invasive staging of liver fibrosis in patients with chronic hepatitis C
title_fullStr Role of (13)C methacetin breath test for non invasive staging of liver fibrosis in patients with chronic hepatitis C
title_full_unstemmed Role of (13)C methacetin breath test for non invasive staging of liver fibrosis in patients with chronic hepatitis C
title_short Role of (13)C methacetin breath test for non invasive staging of liver fibrosis in patients with chronic hepatitis C
title_sort role of (13)c methacetin breath test for non invasive staging of liver fibrosis in patients with chronic hepatitis c
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181145/
https://www.ncbi.nlm.nih.gov/pubmed/25222787
work_keys_str_mv AT fierbinteanubraticevicicarmen roleof13cmethacetinbreathtestfornoninvasivestagingofliverfibrosisinpatientswithchronichepatitisc
AT papacocearaluca roleof13cmethacetinbreathtestfornoninvasivestagingofliverfibrosisinpatientswithchronichepatitisc
AT tribuslaura roleof13cmethacetinbreathtestfornoninvasivestagingofliverfibrosisinpatientswithchronichepatitisc
AT cristianbaicus roleof13cmethacetinbreathtestfornoninvasivestagingofliverfibrosisinpatientswithchronichepatitisc